Follow the latest coverage, related explainers and connected technology stories.
A study funded by Dexcom and published in the New England Journal of Medicine found that using the Dexcom G7 improved HbA1c levels and time in the target range among people with type 2 diabetes who do not use insulin. The findings come as Dexcom awaits a decision from CMS on expanding Medicare coverage for these devices.
UK-based Sava Technologies raised $36 million in a Series B round led by Ascensia Diabetes Care, which also received exclusive rights to market and distribute the sensor in Europe. The company aims to launch a wearable sensor after conducting a pivotal trial and seek CE marking within the next two years.
Oura filed for an initial public offering that could be worth up to $2.2 billion, offering 50 million shares at an estimated price of between $40 and $44 per share. The offering comes as the company expands its health features, while facing regulatory questions and a proposed lawsuit concerning the accuracy of sleep tracking.
The Centers for Medicare and Medicaid Services is expanding the ACCESS program to include heart failure, chronic obstructive pulmonary disease, substance use disorders, and smoking cessation, while extending support for certain musculoskeletal conditions. The program combines outcome-linked payments with a regulatory pathway for collecting real-world data on certain digital health technologies.
Beta Bionics has received U.S. Food and Drug Administration clearance for the Mint wearable insulin pump, which is worn for three days and holds 200 units of insulin. The company plans to launch it in the United States during the first quarter of 2027 through pharmacy channels, opening direct competition with Insulet.
The U.S. Food and Drug Administration is developing guidance for using generative artificial intelligence in medical devices, focusing on competency-based evaluation, foundation models, and post-market monitoring. Fundamental questions remain open about the limits of oversight and companies’ responsibility for declining model performance over time.
Dexcom and Abbott are awaiting a CMS decision that could expand Medicare coverage for continuous glucose monitoring devices to include patients with type 2 diabetes who do not use insulin. Dexcom expects the decision before the end of 2026, with potential coverage beginning in mid-2027.
The FDA selected three manufacturers to participate in the TEMPO pilot program, which aims to expand access to digital health devices intended to improve outcomes for patients with chronic diseases under the ACCESS model. The companies will collect real-world use data, while the FDA has not yet evaluated the effectiveness of the devices for the specific uses covered by the program.